Metrion Biosciences, a Cambridge, UK-based ion channel CRO and drug discovery company, raised £3.7M in funding.
The round was led by Maven Capital Partners, alongside Gresham House Ventures.
The company intends to use the funds to to further expand its laboratories in Cambridge, UK, invest in specialist equipment and enhance global marketing activities.
Metrion Biosciences is a contract research organisation specialising in providing a range of ion channel drug discovery services for its customers. Its approach offers a dedicated, flexible service used to each customer’s requirements. It is supported by rapid reporting and data interpretation by its experienced ion channel team. These services include compound screening assays, detailed characterisation of lead compounds in human cells and native tissue, as well as confirmation of efficacy in stem cell and other phenotypic models.
Metrion also announced the appointment of Dr David Milroy and Steve Carle to the board. At the same time, Dr Marc Rogers, Dr Barry Kenny and Mark Keogh have retired as non-executive directors of the company.
Metrion Biosciences, a Cambridge, UK-based ion channel CRO and drug discovery company, raised £3.7M in funding. Best wishes to everyone in the group. This will be a huge accomplishment for them in the future.
Shishir Gupta, The Founder & CEO of StartupLanes
About us: StartupLanes is an ecosystem for Startups and Investors. Collaborate or find a co-founder, it’s a platform for Entrepreneurs. We love startups! A place for Angel Investors and Venture Capitalists to find investing opportunities in startups. Validate your idea, Learn & Execute.
Startups looking for funding may apply through StartupLanes Funding Application.
Angel Investors Register Free to explore exciting startup investment opportunities.